公司新闻(英文)
April 30, 2018 / 1:13 PM / 7 months ago

BRIEF-Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 Aspire Study To Kyprolis Label

1 分钟阅读

April 30 (Reuters) - Amgen Inc:

* AMGEN RECEIVES POSITIVE CHMP OPINION TO ADD OVERALL SURVIVAL RESULTS FROM THE PHASE 3 ASPIRE STUDY TO KYPROLIS® (CARFILZOMIB) LABEL Source text for Eikon: Further company coverage:

我们的标准：汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below